Hojatollah Rezaei Nejad

Noven Pharmaceuticals, Inc. operates as a pharmaceutical company with transdermal expertise. It specializes in the research and development, manufacture, marketing, and sale of prescription pharmaceutical products. The company was founded in 1987 and is headquartered in Miami, FL.

Part of Squire Patton Boggs (US) LLP, Steel Hector & Davis LLP provides legal services. The company is based in Miami, FL. Steel Hector & Davis was acquired by Squire Sanders (US) LLP on September 06, 2005.

Noven Therapeutics LLC develops and distributes pharmaceutical products. It markets products which include Pexeva used for major depressive disorder, panic disorder (PD), obsessive compulsive disorder (OCD) and Lithobid for bipolar disorder. The company was founded by Phillip M. Satow and Michael S. Satow in 2003 and is headquartered in New York, NY.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Topokine Therapeutics, Inc. develops therapies for dermatology and medical aesthetics. Its product, the XAF5 Gel, reduces excess subcutaneous fat. The XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. The company was founded in 2010 and is headquartered in Madison, NJ.

Pykus Therapeutics, Inc. engages in the development of a dissolvable intraocular surgical device. It offers novel polymer that provides retinal tamponade. The company was founded by James Stefater and Tomasz Stryjewski and is headquartered in Boston, MA.

Cartesian Therapeutics, Inc. manufacturers biological products. The company was founded by Murat Kalayoglu and Michael Singer in 2016 and is headquartered in Gaithersburg, MD.

Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation.